
Our challenge is defining the regulatory framework in which we are classed, so in the end, patients can receive our therapies
Tags:
Merck Sharp & Dohme (MSD) Spain’s Ana Argelich Hesse comments on how the big changes experienced by the global organization in 2021, including a new CEO and the spinoff of…
The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics and biosimilars in the country and shares his…
Organon’s general manager for Spain and Portugal, Juan Vera, explains the challenges of executing the spinoff from MSD in the middle of the pandemic, the reasons why his affiliate has…
See our Cookie Privacy Policy Here